StockData
IGC Pharma, Inc. logo

IGC Pharma, Inc. (IGC) stock

IGCNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 2/3019% above fair value
$0.19+0.01 (+7.37%)

Close on Nov 17, 2026Market cap $19.43MP/E –Yield –

IGC Pharma revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

IGC Pharma's revenue for the twelve months ending Jun 30, 2026 was $1.12M, down 15.4% year over year. For fiscal 2025 it was $1.27M, down 5.5% from the year before. Over ten years it grew -16.5% a year on average. The highest annual figure on record is $8.03M in fiscal 2013.

Annual revenue

PeriodPeriod endValueChange
FY2025Mar 31, 2025$1.27M-5.5%
FY2024Mar 31, 2024$1.35M+47.6%
FY2023Mar 31, 2023$911.00K+129.5%
FY2022Mar 31, 2022$397.00K-55.8%
FY2021Mar 31, 2021$898.00K-77.9%
FY2020Mar 31, 2020$4.07M-20.4%
FY2019Mar 31, 2019$5.12M+133.3%
FY2018Mar 31, 2018$2.19M+277.9%
FY2017Mar 31, 2017$580.37K-90.9%
FY2016Mar 31, 2016$6.37M-17.1%
FY2015Mar 31, 2015$7.68M+237.9%
FY2014Mar 31, 2014$2.27M-71.7%
FY2013Mar 31, 2013$8.03M+91.2%
FY2012Mar 31, 2012$4.20M–

Quarterly revenue

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jun 30, 2026$265.00K-19.2%
Q4 FY2026CQ1 2026Mar 31, 2026$317.00K-3.9%
Q3 FY2026CQ4 2025Dec 31, 2025$350.00K+36.2%
Q2 FY2026CQ3 2025Sep 30, 2025$191.00K-53.6%
Q1 FY2026CQ2 2025Jun 30, 2025$328.00K+20.6%
Q4 FY2025CQ1 2025Mar 31, 2025$330.00K+11.9%
Q3 FY2025CQ4 2024Dec 31, 2024$257.00K+26.0%
Q2 FY2025CQ3 2024Sep 30, 2024$412.00K+41.6%
Q1 FY2025CQ2 2024Jun 30, 2024$272.00K-51.0%
Q4 FY2024CQ1 2024Mar 31, 2024$295.00K+77.7%
Q3 FY2024CQ4 2023Dec 31, 2023$204.00K-38.6%
Q2 FY2024CQ3 2023Sep 30, 2023$291.00K+44.1%
Q1 FY2024CQ2 2023Jun 30, 2023$555.00K+161.8%
Q4 FY2023CQ1 2023Mar 31, 2023$166.00K+36.1%
Q3 FY2023CQ4 2022Dec 31, 2022$332.00K+133.8%
Q2 FY2023CQ3 2022Sep 30, 2022$202.00K+260.7%
Q1 FY2023CQ2 2022Jun 30, 2022$212.00K+175.3%
Q4 FY2022CQ1 2022Mar 31, 2022$122.00K+50.6%
Q3 FY2022CQ4 2021Dec 31, 2021$142.00K+31.5%
Q2 FY2022CQ3 2021Sep 30, 2021$56.00K-55.2%
Q1 FY2022CQ2 2021Jun 30, 2021$77.00K-86.8%
Q4 FY2021CQ1 2021Mar 31, 2021$81.00K+179.3%
Q3 FY2021CQ4 2020Dec 31, 2020$108.00K-81.2%
Q2 FY2021CQ3 2020Sep 30, 2020$125.00K-93.1%
Q1 FY2021CQ2 2020Jun 30, 2020$584.00K-64.6%
Q4 FY2020CQ1 2020Mar 31, 2020$29.00K-98.1%
Q3 FY2020CQ4 2019Dec 31, 2019$573.00K-55.4%
Q2 FY2020CQ3 2019Sep 30, 2019$1.82M+124.5%
Q1 FY2020CQ2 2019Jun 30, 2019$1.65M+11.6%
Q4 FY2019CQ1 2019Mar 31, 2019$1.54M+35.0%
Q3 FY2019CQ4 2018Dec 31, 2018$1.29M+68.6%
Q2 FY2019CQ3 2018Sep 30, 2018$811.00K+245.1%
Q1 FY2019CQ2 2018Jun 30, 2018$1.48M+2692.6%
Q4 FY2018CQ1 2018Mar 31, 2018$1.14M+1127.9%
Q3 FY2018CQ4 2017Dec 31, 2017$762.00K+205.0%
Q2 FY2018CQ3 2017Sep 30, 2017$235.00K+44.9%
Q1 FY2018CQ2 2017Jun 30, 2017$52.93K–
Q4 FY2017CQ1 2017Mar 31, 2017$93.01K–
Q3 FY2017CQ4 2016Dec 31, 2016$249.80K–
Q2 FY2017CQ3 2016Sep 30, 2016$162.16K–

More IGC Pharma figures

See a number that looks wrong?